ELECTROLYTE COMPOSITION OF SURFACE FLUID IN NORMAL AND CF AIRWAY EPITHELIA

正常和 CF 气道上皮表面液体的电解质组成

基本信息

  • 批准号:
    6668332
  • 负责人:
  • 金额:
    $ 24.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-09-01 至 2003-08-31
  • 项目状态:
    已结题

项目摘要

(Adapted from the applicant's abstract) The investigators recently proposed a hypothesis to link the molecular and physiologic defect in CF, loss of CFTR C1- channel function and defective transepithelial C1- transport, with the clinical hallmark of CF, airway infections. They and others found that both normal and CF airway epithelia secrete antibacterial substances into the thin layer of fluid covering the apical surface. However the killing activity of these factors require a low NaC1 concentration. Reports that CF surface fluid has a high NaC1 concentration would explain the lack of bacterial killing in CF. They will test three hypotheses about the electrolyte composition of airway surface fluid. First, the salt concentration of airway surface fluid is increased in CF. To test this hypothesis investigators will use primary cultures of normal and CF airway epithelia to measure ion concentrations of ASF, as well as in vivo measurements done in animals and humans. Second, the increase in ASF salt concentration in CF is due to impaired electrolyte absorption. They will test the hypothesis by asking how normal and CF epithelia modify the electrolyte composition of ASF. Third, interventions that decrease salt concentration will restore bactericidal activity. To test this hypothesis they will restore CFTR function by gene transfer, activate alternative (non-CFTR) C1 channels and block epithelial Na+ channels. Investigators will also attempt to use novel approaches to decrease the concentration of salt in ASF. Given its importance, it is surprising that the composition of ASF is not better understood. The studies proposed should provide new insight into the electrolyte concentration of ASF and how they are modified. The results are central to understanding how the lack of CFTR C1- channels causes CF lung disease and to develop new therapies.
(改编自申请人摘要)研究人员最近提出了一项 将CF中的分子和生理缺陷、CFTR的丧失 C1通道功能和跨上皮C1转运缺陷, CF的临床特征,呼吸道感染。他们和其他人发现, 正常和CF气道上皮细胞分泌抗菌物质进入薄 覆盖顶端表面的液体层。然而, 这些因素需要低的NaCl浓度。报告称CF表面流体 具有高NaCl浓度可以解释细菌缺乏杀伤力, 参见 他们将检验关于气道电解质组成的三个假设, 表面流体首先,气道表面流体的盐浓度是 增加了CF。为了验证这一假设,研究人员将使用主要的 培养正常和CF气道上皮细胞,以测量 ASF,以及在动物和人类中进行的体内测量。二是 CF中ASF盐浓度增加是由于电解质受损 吸收他们将通过询问正常和CF 上皮细胞改变ASF的电解质组成。第三,干预措施 降低盐浓度将恢复杀菌活性。测试 这一假设,他们将恢复CFTR功能的基因转移,激活 替代(非CFTR)C1通道和阻断上皮Na+通道。 研究人员还将尝试使用新的方法来减少 ASF中盐的浓度。 鉴于其重要性,令人惊讶的是,ASF的组成并不 更好地理解。拟议的研究应提供新的见解, ASF的电解质浓度以及它们如何被修改。结果 理解CFTR C1通道的缺乏如何导致CF肺的核心 疾病和开发新的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph Zabner其他文献

Joseph Zabner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph Zabner', 18)}}的其他基金

In Vitro Models and Cell Culture Core
体外模型和细胞培养核心
  • 批准号:
    10470333
  • 财政年份:
    2020
  • 资助金额:
    $ 24.35万
  • 项目类别:
In Vitro Models and Cell Culture Core
体外模型和细胞培养核心
  • 批准号:
    10248525
  • 财政年份:
    2020
  • 资助金额:
    $ 24.35万
  • 项目类别:
In Vitro Models and Cell Culture Core
体外模型和细胞培养核心
  • 批准号:
    10024663
  • 财政年份:
    2020
  • 资助金额:
    $ 24.35万
  • 项目类别:
In Vitro Models and Cell Culture Core
体外模型和细胞培养核心
  • 批准号:
    10677585
  • 财政年份:
    2020
  • 资助金额:
    $ 24.35万
  • 项目类别:
Ancillary Study 1
辅助研究1
  • 批准号:
    7934327
  • 财政年份:
    2010
  • 资助金额:
    $ 24.35万
  • 项目类别:
Directed evolutioni of AAV for gene theraphy in a pig model of cystic fibrosis
用于囊性纤维化猪模型基因治疗的 AAV 定向进化
  • 批准号:
    7741474
  • 财政年份:
    2009
  • 资助金额:
    $ 24.35万
  • 项目类别:
Cell Culture Core
细胞培养核心
  • 批准号:
    7741487
  • 财政年份:
    2009
  • 资助金额:
    $ 24.35万
  • 项目类别:
Request for Funds to Purchase a Replacement Laser Scanning Confocal Microscope
申请资金购买替换激光扫描共焦显微镜
  • 批准号:
    7591586
  • 财政年份:
    2009
  • 资助金额:
    $ 24.35万
  • 项目类别:
Project 3: Contribution of Small Airways to Cystic Fibrosis Lung Disease Pathogenesis
项目 3:小气道对囊性纤维化肺病发病机制的贡献
  • 批准号:
    10226940
  • 财政年份:
    2008
  • 资助金额:
    $ 24.35万
  • 项目类别:
Project 3: Contribution of Small Airways to Cystic Fibrosis Lung Disease Pathogenesis
项目 3:小气道对囊性纤维化肺病发病机制的贡献
  • 批准号:
    10470212
  • 财政年份:
    2008
  • 资助金额:
    $ 24.35万
  • 项目类别:

相似海外基金

Development of rapid detection method for drug-resistant bacteria in pulmonary MAC disease and search for new antibacterial agents
肺部MAC疾病耐药菌快速检测方法的建立及新型抗菌药物的寻找
  • 批准号:
    23K07930
  • 财政年份:
    2023
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of novel antibacterial agents using crystal structure-based drug screening
利用基于晶体结构的药物筛选开发新型抗菌剂
  • 批准号:
    23K07918
  • 财政年份:
    2023
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections
ATP 合酶作为针对耐药细菌感染的广谱抗菌药物临床前开发的新兴靶标
  • 批准号:
    472342
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Operating Grants
Clinical application of a rapid assay for antibacterial susceptibility test of beta-lactams and carbapenems antibacterial agents using MALDI-TOF MS
MALDI-TOF MS快速测定β-内酰胺类和碳青霉烯类抗菌药物药敏试验的临床应用
  • 批准号:
    22K07406
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Tailored and uniform fibre-like micelles as antibacterial agents.
定制且均匀的纤维状胶束作为抗菌剂。
  • 批准号:
    569719-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
  • 批准号:
    531450-2018
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
  • 批准号:
    521908-2018
  • 财政年份:
    2021
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
  • 批准号:
    531450-2018
  • 财政年份:
    2021
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
  • 批准号:
    521908-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents.
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体。
  • 批准号:
    531450-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 24.35万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了